ClinicalTrials.gg
RecruitingNCT05151809PBC322Updated Jul 25, 2025

National Database on Primary Biliary Cholangitis

An observational study in Primary Biliary Cholangitis, sponsored by University of Milano Bicocca. Recruiting at 55 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by University of Milano Bicocca · Observational

How we know

From the registry’s dates

  • Started Sep 2019; still recruiting 7 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Liver Cirrhosis, Biliary with a site in Italy — 5 open to participants now, 11 under way, 4 of them phase 3. Liver Cirrhosis, Biliary · Italy.

Started
2019
the only one that year
Observational
5 of 25
3 open now
Primary completion
2029-01
later than 7 of 10 live
Registered
14th of 25
by date

Among the 25 studies in Liver Cirrhosis, Biliary with a site in Italy, this one is the only one that started in 2019, is one of 5 observational ones, reaches primary completion later than 7 of the 10 other live ones, and was the 14th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

5 of the 25 studies in Liver Cirrhosis, Biliary with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Liver Cirrhosis, Biliary with a site in Italy, or all of them as a file.
02

Study summary

Primary biliary cholangitis (PBC) is a rare, autoimmune, cholestatic liver disease. No data about the disease epidemiology exist in Italy. Therefore this study aims to develop a national PBC patient database linked to a biological sample storage.

Read the detailed description

Primary biliary cholangitis (PBC) is an immune-mediated liver disease characterized by chronic inflammation of the intrahepatic bile ducts, causing progressive ductopenia, cholestasis, and if not effectively treated, leading to fibrosis, cirrhosis and liver failure. Nowadays almost all patients with PBC are diagnosed at an early disease stage and receive treatment with ursodeoxycholic acid (UDCA) which is currently the only drug approved for the treatment of patients with PBC. However, approximately 20% to 30% (up to >50% in patients presenting under the age of 40 years) still does not have a benefit from UDCA and has a reduced prognosis as compared to healthy individuals. Major steps forwards in the field of PBC have been done in the last decade, however there are still significant areas of unmet clinical need in PBC: the lack of knowledge on etiopathogenesis; a poor understanding of disease sub-phenotypes; the lack of biomarkers of disease progression that allow risk stratification needed in clinical management and trials design, among the others. In the current evolving research landscape with the availability of the -omics technologies generating libraries of genome-wide data, metabolomics and proteomics data, among the others, the prospects of discovering the gene and molecular underpinnings of PBC are more promising than ever. Scientists envision an era of "personalized medicine" when more and more people will obtain their own genetic and metabolic maps, enabling them to identify their status as carriers of specific risk profiles.

Based on these premises, the current project aims to build up a research, nation-wide infrastructure (around 60 Italian participating centres will be involved) to study the biology of PBC and, in particular, to explore why a significant group of, typically young patients fail primary therapy with UDCA, placing them at risk of developing progressive disease and needing liver transplantation (LT). The investigators will recruit patients and organise the collection of important clinical information and laboratory investigation, together with biological samples. Data will be collected in the form of electronic Case Report Forms (REDCap cloud) that will be completed by clinicians at baseline and thereafter on an annual basis. The clinical information will allow us to identify patients' clinical profiles. The biological samples will allow to understand key aspects of people's make up, including patient genes and the way their immune system works, and the differences in make up between people with different clinical phenotypes.

This research infrastructure would represent an invaluable resource for successful translational research in this field. Specifically, it would serve investigators conducting research; clinicians treating patients; epidemiologists gathering demographic data; and the drug and device industry seeking new markets. It also can represent a necessary infrastructure for the implementation of the European Reference Networks (ERN) for rare diseases, main pillars of the current EU policy framework on National Plans for research and development. The Italian PBC database would also be crucial for drug development, specifically to assess the feasibility of clinical trials, to facilitate the planning of appropriate clinical trials, to support the enrolment of patients and to assess the impact of new interventions.

03

Conditions studied

  • Primary Biliary Cholangitis

Keywords

  • Primary Biliary Cholangitis
  • Disease phenotypes
  • National Database
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All the italian patients fulfilling the diagnostic criteria for Primary Biliary Cholangitis (European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009 Aug;51(2):237-67) and aged at least 18.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All PBC patients living in Italy and aged at least 18 years can be included in the database. According to well-established criteria, PBC is diagnosed in subjects who fulfill two of the three of following criteria:

  • elevated alkaline phosphatase and /or GGT;
  • positive anti-mitochondrial autoantibodies (titer ≥ 1:40) or PBC-specific antinuclear antibodies (gp-210 and sp100);
  • characteristic histological features of florid bile ducts lesions and granulomatous lesion.

Exclusion criteria

Exclusion Criteria:

The patient has explicitly declared his/her unwillingness to participate to the study

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • PBC population residing in Italy

    All PBC patients living in Italy and aged at least 18 years can be included in the database. According to well-established criteria, PBC is diagnosed in subjects who fulfill two of the three of following criteria: 1. elevated alkaline phosphatase and /or GGT; 2. positive anti-mitochondrial autoantibodies (titer ≥ 1:40) or PBC-specific antinuclear antibodies (gp-210 and sp100); 3. characteristic histological features of florid bile ducts lesions and granulomatous lesion.

    Other: Clinical information

Interventions

  • OtherClinical information

    The investigators will recruit PBC patients and collect important clinical information and laboratory investigation, together with biological samples.

    Also known as: Laboratory information, Biological samples

06

What researchers measure

Primary outcomes

  1. Phenotypes and sub-phenotypes of PBC Italian patients

    Identify and define distinct phenotypes and sub-phenotypes of PBC patients at higher risk of disease progression.

    Time frame: Overall duration of the study (10 years)

Secondary outcomes

  1. Response to UDCA therapy

    Defined as Alkaline Phosphatase Level\<1 x upper limit of normal. The investigators will fit a multivariate analysis using logistic regression using baseline variables.

    Time frame: Overall duration of the study (10 years)

  2. Identification of factors influencing the progression of PBC

    The investigators will calculate the time from the diagnosis of PBC to an event (liver decompensation, liver transplantation or death). They will then fit a multivariate analysis using Cox's proportional hazards regression model of diverse explanatory variables available at baseline.

    Time frame: Overall duration of the study (10 years)

  3. Safety and long-term efficacy of novel therapies

    The investigators will evaluate prospectively laboratory investigation and the treatment response to novel therapies that are entering the clinical practice, e.g. obeticholic acid, fibrates.

    Time frame: Overall duration of the study (10 years)

07

Study locations

50 of 55 sites recruiting
  • Ospedali riuniti di Ancona
    Ancona, Italy
    Recruiting
  • A.O.U. Consorziale - Policlinico Bari- UO Gastroenterologia
    Bari, Italy
    Recruiting
  • UO di gastroenterologia, Asst Papa Giovanni XXIII
    Bergamo, Italy
    Recruiting
  • Policlinico S. Orsola Malpighi- UO Medicina Interna
    Bologna, Italy
    Recruiting
  • Policlinico S.Orsola Malpighi- Ambulatorio di epatologia e gestione trapianto epatico
    Bologna, Italy
    Not yet recruiting
  • Gastroenterologia, fisiopatologia e endoscopia digestiva, Azienda sanitaria dell'alto adige
    Bolzano, Italy
    Recruiting
  • Unità epatologica ed ecografia internistica a valenza dipartimentale, Fondazione Ospedaliera Poliambulanza
    Brescia, Italy
    Recruiting
  • UO di gastroenterologia, Spedali civili di Brescia
    Brescia, Italy
    Not yet recruiting
  • UO epatologia, Azienda ospedaliero università di Cagliari Policlinico universitario Monserrato
    Cagliari, Italy
    Recruiting
  • Ospedale IRCCS Saverio De Bellis- UOC di Gastroenterologia 1
    Castellana Grotte, Italy
    Recruiting
  • UO epatologia Ospedale Garibaldi
    Catania, Italy
    Recruiting
  • UO di fisiopatologia digestiva, Azienda Ospedaliera Universitaria Mater Domini
    Catanzaro, Italy
    Recruiting
  • UO di gastroenterologia, Ospedale Valduce
    Como, Italy
    Recruiting
  • Azienda Socio Sanitaria Territoriale (ASST) di Cremona- UO Medicina Interna - Ambulatori di Epatologia
    Cremona, Italy
    Recruiting
  • Presidio Ospedaliero di Faenza- UO Medicina Interna
    Faenza, Italy
    Recruiting
  • UO Clinica Medica, Azienda Ospedaliera Universitaria Careggi Firenze
    Florence, Italy
    Recruiting
  • Centro C.U.R.E. Centro Universitario per la ricerca e la Cura delle Malattie Epatiche
    Foggia, Italy
    Recruiting
  • Ambulatorio di Malattie del Fegato, U.O. Medicina, ASST Valle Olona, Presidio di Gallarate
    Gallarate, Italy
    Recruiting
  • UO Clinica Gastroenterologica, Policlinico San Martino
    Genova, Italy
    Recruiting
  • Centro Medicina del Viaggiatore e delle Migrazioni, ASP Catanzaro, Presìdio Ospedaliero "Giovanni Paolo II"
    Lamezia Terme, Italy
    Recruiting
  • UO di epatologia clinica e biomolecolare, Università degli studi di Messina
    Messina, Italy
    Not yet recruiting
  • University of Milano-Bicocca
    Milan, 20126, Italy
    Recruiting
  • Policlinico di Milano
    Milan, Italy
    Recruiting
  • UO di epatologia, Ospedale Niguarda Ca' Granda
    Milan, Italy
    Recruiting
  • UO di Epatologia, Ospedale San Giuseppe
    Milan, Italy
    Recruiting
  • UO epatologia, Istituto scientifico universitario San Raffaele
    Milan, Italy
    Recruiting
  • AOU di Modena- U.O. Gastroenterologia
    Modena, Italy
    Recruiting
  • Struttura Complessa di Medicina ad Indirizzo Metabolico Nutrizionale, Dipartimento Ospedaliero di Medicina Interna
    Modena, Italy
    Recruiting
  • Day Hospital e Ambulatorio di Epatoogia e Nutrizione Clinica, Fondazione Evangelica Villa Betania, Ospedale generale di Zona
    Naples, Italy
    Not yet recruiting
  • Ospedale policlinico Federico II di Napoli
    Naples, Italy
    Recruiting
  • Università della Campania Luigi Vanvitelli di Napoli- Dipartimento di epato-gastroenterologia
    Naples, Italy
    Recruiting
  • UO medicina ed epatologia, Ospedale maggiore della carità
    Novara, Italy
    Recruiting
  • UO di Gastroenterologia, Azienda ospedaliera di Padova
    Padova, Italy
    Recruiting
  • UO di Medicina Interna, Azienda Ospedaliera di Padova
    Padova, Italy
    Recruiting
  • UO gastroenterologia, Policlinico Paolo Giaccone
    Palermo, Italy
    Recruiting
  • Malattie infettive ed epatologia, Azienda ospedaliero universitaria di Parma
    Parma, Italy
    Recruiting
  • Day Hospital Internistico e ambulatorio di Epatologia, ASL Pescara
    Pescara, Italy
    Recruiting
  • UO epatologia, AOU pisana Cisanello
    Pisa, Italy
    Recruiting
  • S.C. Gastroenterologia, Ospedale di Pordenone, AS FO
    Pordenone, Italy
    Recruiting
  • Medicina clinica ed epatologia, Policlinico universitario campus bio-medico
    Roma, Italy
    Recruiting
  • Policlinico Universitario Fondazione Agostino Gemelli- UO di medicina interna
    Roma, Italy
    Recruiting
  • UO di Epatologia, Universita' di Roma Tor Vergata
    Roma, Italy
    Recruiting
  • UO di Gastroenterologia, Policlinico Umberto I
    Roma, Italy
    Recruiting
  • Medicina interna ed epatologia, Istituto clinico Humanitas
    Rozzano, Italy
    Recruiting
  • Università degli studi di Salerno
    Salerno, Italy
    Recruiting
  • SSD Epatologia, Fondazione Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Italy
    Not yet recruiting
  • UO di Gastroenterologia e Endoscopia Digestiva, Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Italy
    Recruiting
  • Azienda Ospedale Universitaria di Sassari- UOC Medicina Interna
    Sassari, Italy
    Recruiting
  • S.C. Gastroenterologia, Azienda Ospedaliero-Universitaria Molinette
    Torino, Italy
    Recruiting
  • Gastroenterologia ed endoscopia digestiva, Azienda provinciale per i servizi sanitari
    Trento, Italy
    Recruiting
  • Ospedale regionale Ca' Foncello di Treviso- Unità operativa complessa di Gastroenterologia
    Treviso, Italy
    Recruiting
  • SC (UCO) Clinica Patologie del Fegato, Ospedale di Cattinara, ASU GI
    Trieste, Italy
    Recruiting
  • SOS di DPT Epatologia e Trapianti di Fegato, ASU FC
    Udine, Italy
    Recruiting
  • UO di gastroenterologia ed endoscopia digestiva, Azienda macchi, Asst sette laghi
    Varese, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Integrata Verona- UOC Gastroeneterologia A
    Verona, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2019 (actual). Primary completion is estimated for Jan 2029, 112 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Dec 9, 2021
StartActual
Sep 19, 2019
Primary completionEst.
Jan 24, 2029
CompletionEst.
Jan 24, 2029
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05151809
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
Sep 19, 2019
Primary completion
Jan 24, 2029 (estimated)
Completion
Jan 24, 2029 (estimated)
Last update
Jul 25, 2025

Study contacts

Pietro Invernizzi, MD
Contact
pietro.invernizzi@unimib.it
+39 039 233 2187
Marco Carbone, MD
Contact
marco.carbone@unimib.it
02 6448 8139

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion